137 related articles for article (PubMed ID: 11565828)
1. Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation.
Heslop HE
J Immunother; 2001; 24(4):283-4. PubMed ID: 11565828
[No Abstract] [Full Text] [Related]
2. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
[No Abstract] [Full Text] [Related]
3. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.
Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P
J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063
[TBL] [Abstract][Full Text] [Related]
4. [Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases].
Kuzushima K
Rinsho Ketsueki; 2000 Jun; 41(6):487-90. PubMed ID: 10921347
[No Abstract] [Full Text] [Related]
5. EBV specific CTL: a model for immune therapy.
Rooney CM; Heslop HE; Brenner MK
Vox Sang; 1998; 74 Suppl 2():497-8. PubMed ID: 9704488
[TBL] [Abstract][Full Text] [Related]
6. Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.
Haque T; Crawford DH
Springer Semin Immunopathol; 1998; 20(3-4):375-87. PubMed ID: 9870252
[No Abstract] [Full Text] [Related]
7. Virus-specific cytotoxic T lymphocytes as prophylaxis for Epstein-Barr virus lymphoproliferative disease in pediatric bone marrow transplant recipients.
Norville R; Nance D; Cheshire S
J Pediatr Oncol Nurs; 1997 Oct; 14(4):194-201. PubMed ID: 9322393
[TBL] [Abstract][Full Text] [Related]
8. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
Smith CA; Ng CY; Heslop HE; Holladay MS; Richardson S; Turner EV; Loftin SK; Li C; Brenner MK; Rooney CM
J Hematother; 1995 Apr; 4(2):73-9. PubMed ID: 7633844
[TBL] [Abstract][Full Text] [Related]
9. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants.
Meijer E; Dekker AW; Weersink AJ; Rozenberg-Arska M; Verdonck LF
Br J Haematol; 2002 Dec; 119(3):596-607. PubMed ID: 12437632
[No Abstract] [Full Text] [Related]
10. Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children.
Fletcher BD; Heslop HE; Kaste SC; Bodner S
Pediatr Radiol; 1998 Jul; 28(7):492-6. PubMed ID: 9662565
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T cells and immunotherapy.
Kitchingman GR; Rooney C
Pediatr Radiol; 1998 Jul; 28(7):489-91. PubMed ID: 9662564
[TBL] [Abstract][Full Text] [Related]
12. T-Cell-Based Immune Therapy Treats EBV-LPD.
Cancer Discov; 2015 Jul; 5(7):OF12. PubMed ID: 25968118
[No Abstract] [Full Text] [Related]
13. B-cell enrichment and infusion in CD4+/CD8+ T-cell depleted products for donor innate immune lymphocyte infusion: is risk of EBV-associated lymphocyte post transplantation lymphoproliferative disease a concern?
Lamb LS; Sande J
Bone Marrow Transplant; 2008 Jun; 41(11):995-6. PubMed ID: 18278072
[No Abstract] [Full Text] [Related]
14. Epstein-Barr virus and lymphoproliferative disorders after transplantation.
Am J Transplant; 2004 Nov; 4 Suppl 10():59-65. PubMed ID: 15504214
[No Abstract] [Full Text] [Related]
15. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
16. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; Brenner MK; Heslop HE
Lancet; 1995 Jan; 345(8941):9-13. PubMed ID: 7799740
[TBL] [Abstract][Full Text] [Related]
17. [Epstein-Barr virus infection in patients after bone marrow and heart transplantation].
Zawilińska B; Gruszka K; Piatkowska-Jakubas B; Garlicki M; Skotnicki A
Przegl Epidemiol; 2001; 55 Suppl 3():52-5. PubMed ID: 11984959
[TBL] [Abstract][Full Text] [Related]
18. The antiviral prophylaxis of post-transplant lymphoproliferative disorder.
Davis CL
Springer Semin Immunopathol; 1998; 20(3-4):437-53. PubMed ID: 9870256
[No Abstract] [Full Text] [Related]
19. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
[TBL] [Abstract][Full Text] [Related]
20. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.
O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
Immunol Rev; 1997 Jun; 157():195-216. PubMed ID: 9255631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
